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Abstract
Asplenic patients have a lifelong risk of overwhelming post-splenectomy infection and have been reported to have low
numbers of peripheral blood IgM memory B cells. The clinical value of quantitation of memory B cells as an indicator of
splenic abnormality or risk of infection has been unclear. To assess changes in B cell sub-populations after splenectomy we
studied patients recruited to a spleen registry (n=591). A subset of 209 adult asplenic or hyposplenic subjects, and normal
controls (n=140) were tested for IgM memory B cells. We also determined a) changes in IgM memory B cells with time after
splenectomy using the cross-sectional data from patients on the registry and b) the kinetics of changes in haematological
markers associated with splenectomy(n=45). Total B cells in splenectomy patients did not differ from controls, but memory
B cells, IgM memory B cells and switched B cells were significantly (p,0.001) reduced. The reduction was similar for different
indications for splenectomy. Changes of asplenia in routine blood films including presence of Howell-Jolly bodies (HJB),
occurred early (median 25 days) and splenectomy associated thrombocytosis and lymphocytosis peaked by 50 days. There
was a more gradual decrease in IgM memory B cells reaching a stable level within 6 months after splenectomy. IgM memory
B cells as proportion of B cells was the best discriminator between splenectomized patients and normal controls and at the
optimal cut-off of 4.53, showed a true positive rate of 95% and false positive rate of 20%. In a survey of 152 registry patients
stratified by IgM memory B cells around this cut-off there was no association with minor infections and no registry patients
experienced OPSI during the study. Despite significant changes after splenectomy, conventional measures of IgM memory
cells have limited clinical utility in this population.
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Introduction
The most clinically significant complication of splenectomy is
overwhelming post-splenectomy infection (OPSI) which occurs in
about 1 in 500 patients per annum and has a mortality of 50% [1–
3]. The organisms causing OPSI are the encapsulated bacteria
including Streptococcus pneumoniae, with others such as Haemophilus
influenzae, and Neisseria meningitidis less common [1]. Although risk
of OPSI has been thought to be highest in the first two years
following splenectomy it may occur at any time [2,4] and can
occur even in those who have been managed with an appropriate
immunization regimen. OPSI in the presence of adequate
immunization may result from infection with serotypes not
covered by the vaccine or because the vaccine failed to elicit an
adequate immune response [4]. Prophylactic antibiotics have been
shown in a randomized controlled trial to be of clear benefit in
children with sickle cell anemia [5] and are advised for adults
following splenectomy in particular during the first 2 years post-
splenectomy [6–8]. Poor compliance is often a limiting factor in
the continuous use of antibiotic prophylaxis [1,9–12]. An assay
that would better stratify risk of OPSI would provide a useful
measure to determine those in whom prophylactic antibiotics
could be discontinued without significant risk.
One proposed assay of splenic B lymphoid function measures
circulating IgM memory B cells; a population of B cells in the
peripheral blood that express the memory cells marker CD27,
high surface IgM and low levels of IgD and which have been
found to be low in young children and in asplenia [13]. These cells
have been shown to correspond phenotypically and by gene
expression array to the splenic marginal zone B cells [14] and have
been shown, albeit in limited numbers of subjects, to be low in
asplenic populations at risk for OPSI [13,15–23] as well as in those
with Common Variable Immuno Deficiency (CVID) or hypo-
gammaglobulinaemia on immunoglobulin replacement [15,16,24]
or in individuals with HIV-1 infection [25–28].
In animal models T independent antibody responses have been
shown to be largely dependent on the marginal zone B cells and
B1 cells and these responses to particulate antigens effect early
bacterial clearance [29,30]. In man such natural antibodies against
pneumococcal polysaccharide produced as T independent re-
sponses are able to bind across serotypes [31]. Humans have been
thought to differ from mice in the lack of B1 cells and in some
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cells circulate as IgM memory B cells in blood [14] while they are
restricted to marginal zone in mice [32]. Although marginal zone
B cells have been shown to contribute to the generation of T cell
dependent antibody responses [33] there is little evidence of
deficient vaccine responses in splenectomized subjects [17].
Nevertheless marginal zones in splenic lymphoid tissue have been
proposed as the predominant source of the circulating IgM
memory cells or marginal zone B cells that can provide early T cell
independent responses during bacteremia [13].
Since marginal zone B cells have been postulated to play a role
in innate B cell defences we sought to determine the potential
clinical value of measurement of circulating IgM memory B cells
after splenectomy as a biomarker of loss of splenic tissue by
examining the distribution of memory B cell subsets in a cohort of
splenectomized or hyposplenic subjects enrolled in a spleen
registry. We compared the distribution of memory B cell subsets
to healthy controls. We showed that the kinetics of loss of IgM
memory B cells after splenectomy was delayed compared to the
earlier onset of lymphocytosis, thrombocytosis and appearance of
red cell changes including appearance of HJBs. In a cross-sectional
analysis, numbers of circulating IgM memory B cells decline in the
first 6 months and thereafter remained stable over many years.
Methods
Objectives
The study was designed to quantify the changes in B cell subsets
in asplenic or hyposplenic patients in a population enrolled in a
spleen registry.
Participants
The Victorian Spleen Registry (VSR) was established to provide
ongoing support for management of asplenic and hyposplenic
subjects [7]. The registry was initially established within two
teaching hospital networks in Victoria Australia (Bayside and
Southern Health) that included specialist trauma centers (The
Alfred and Dandenong Hospitals). The enrollments were initially
biased toward incident splenectomy cases. Subsequently the
registry was expanded to become a state-wide registry, that
registered patients with a past history of splenectomy. At the time
of the study there were 591 subjects enrolled.
Bloods from normal healthy controls were obtained from
donors unselected for gender or age (n=35) or as a population
from the Australian Red Cross Blood Service (ARCBS) in
Melbourne (n=105) selected to equally represent donors across
the adult age range from the 3rd to the 7th decade and included
equal numbers of males and females. The initial control
populations consisted of i] laboratory controls to establish the 3
colour flow assay (n=15) and ii] normal laboratory donors used to
establish the 5 colour assay (n=20).
Ethics
Patient consent to enroll with the spleen registry was given at
the time that the referring practitioner completed the registration
form. The referring practitioner had to indicate on the registration
form (tick box) that the patient had been informed that relevant
information and clinical details would be maintained by the
Spleen Registry. If this box on the registration form was not ticked,
the patient was not registered and the referring practitioner was
contacted and asked to provide an amended form confirming
consent prior to the patient being contacted by VSR staff. The
operation of the VSR has been approved by the Human Ethics
and Research Committee of Alfred Health for initial operation 3rd
March 2003, and at the time of adoption of an opt-out recruitment
strategy 30th Aug 2007 and for revised assessment form 4
th Dec
2007.
Procedures
As part of routine assessment and monitoring of registry patients
blood was collected from a subset of patients at varying times after
splenectomy. Measurement of IgM memory B cells was performed
on fresh blood samples at the same time as assessment for asplenic
changes including presence of HJB on a routine blood film
performed by the hematology laboratory service of the hospital.
Most samples were collected at the time of enrollment in the
spleen registry and in some incident splenectomy cases, blood was
collected at routine follow-up within 12 months of splenectomy.
The number of patients from the registry population, controls and
non registry samples used in the different analyses in this study are
shown in figure S1.
Assays of B cell subsets including IgM memory B cells
A 3 colour flow cytometric assay using the surface markers
CD19, CD27, and IgM was initially used to determine the number
of IgM memory B cells in the registry patients. Peripheral blood
mononuclear cells (PBMC) were prepared by standard methods
using Ficoll-Paque density medium (GE Healthcare, Chalfont St.
Giles, United Kingdom) or total white cells were prepared by
adding 200 ml of whole blood to 3 ml of cold RBC lysis buffer
(150 mM NH4Cl, 10 mM KHCO3 1 mM EDTA) for 5 min at
room temperature. The white cells or PBMC were washed once
with FACS wash (Phosphate Buffered Saline, 4 mM EDTA, 1%
newborn calf serum (Cellgro, Invitrogen, San Diego, CA) and
optimal concentration of CD19 ECD (Beckman Coulter), CD27
PE (Beckman Coulter, Fullerton, CA) and anti-IgM FITC (Caltag,
Invitrogen, Carlsbad CA) antibodies were added for 40 minutes
on ice. Cells were washed once in FACS wash (1% FCS and
4 mM EDTA in PBS) and fixed in 200 ml of 1% ultra-pure
formalin (Pierce, Rockford, IL) in PBS. Analysis was performed
within 24 hours using a FACScalibur 4 colour flow cytometer
(Becton Dickinson, Palo Alto, CA). At least 200,000 events were
Figure 1. Representative dot plot profiles and gating strategies for 3 colour (A) and 5 colour (B) flow cytometric analysis of IgM
memory B cells in normal and splenectomy patients. A. i) Lymphocytes were identified by forward (FSC) and side scatter(SSC), ii) B cells by
CD19 expression (% B cells./lymph), iii) memory B cells by CD19, CD27 expression (% memory B cells/B cells), iv) IgM memory B as CD19+CD27+IgM+
(% IgM memory B cells/memory B cells) and switched memory B cells as CD19+CD27+IgM2 (% switched memory B cells/memory B cells).
Lymphocytes were also sequentially gated v) for CD19 CD27+ memory B cells (% memory B cells/lymph) and (vi) for CD27+ and IgM to identify IgM
memory B cells [upper right quadrant] (% IgM memory B cells/B cells) and switched memory B cells [lower right quadrant] (switched memory B cells/B
cells). Parameters used in subsequent quantitative analysis were B cells as a proportion of lymphocytes (ii), memory B cells as a proportion of B cells
(iii) or total lymphocytes (v), and IgM memory cells as a proportion of B cells (vi). B. i) Blood leukocytes were identified by forward (FSC) and side
scatter (SSC), ii) Lymphocytes selected by CD45 and log SSC, iii) B cells were identified by CD19 expression (% B cell/lymph) and iv) memory B cells
were identified as CD19+CD27+IgD
lo cells (% memory B cells/lymph). v) memory B cells were identified as IgD
loIgM+ (% IgM memory B. memory B
cells) and switched memory B cells as CD19+CD27+IgM2IgD2 (% switched memory B cells/memory B cells). vi) lymphocytes gated as B cells and
plotted for IgM and IgD are shown for comparison to identify the predominant naı ¨ve unswitched IgD
hi IgM+ B cell population.
doi:10.1371/journal.pone.0023164.g001
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cells, memory B cells, IgM memory B cells and switched memory
B cells is shown in figure 1A.
For a subset of patients, clinical samples and controls, the 3
colour assay was compared to a 5 colour assay using antibodies to
CD45-ECD (Beckman Coulter), CD19-PE-Cy7(Beckman Coul-
ter), CD27-PE-Cy5(Beckman Coulter), IgM-PE(Caltag) and IgD-
FITC(Caltag). This 5 colour assay was adopted in the clinical
laboratory and was used to establish a normal reference range
from a larger healthy control population. Whole white cells were
obtained by lysis of 100 ml of whole blood in 4 mls of RBC lysis
buffer. Cells were washed once in FACS wash buffer and labeled
with antibody for 25 minutes on ice, washed and fixed with 1%
formalin. Cells were analyzed using an FC500 5 colour flow
cytometer (Beckman Coulter). IgM memory B cells were
sequentially gated as lymphocytes by forward scatter, side scatter,
and expression of CD45, CD19, CD27, IgM and low IgD as
shown in figure 1B.c
Statistical methods
All spleen registry patients with B cell subset determination
(n=209) were compared to the normal reference population and
changes with time analyzed using non-parametric statistical
comparison of samples grouped by time using Mann Whitney U
test. Only a small minority (n=12) had more than one sequential
assay and only one data point from each patient was included in
any of the subgroups analyzed. The first sample was used for cross-
sectional analysis by time and the last available sample was used
for the comparison of B cell changes by cause of splenectomy.
Statistical tests were performed using the program R (v2.5.2)
[34], or SAS version 9.1(SAS Institute, Cary, NC, USA). Measures
of B cell sub-populations were assessed for normality and log
transformed where appropriate. We assessed the effect of
splenectomy, time after splenectomy, age and gender on B cell
measures using the PROC Mixed procedure in SAS. The Mann
Whitney U test was used to compare outcomes for populations
according to the indication for splenectomy and for comparisons
between populations at different times after splenectomy. Results
from the mixed-effects model were presented as parameter
estimates with standard errors or geometric means with 95%
confidence intervals as appropriate. Correlations were performed
using Pearson product moment correlation. Significance was
considered with a probability ,0.05. A Bonferroni correction was
used where appropriate. Analysis of time to appearance of HJB
was performed using the R package survival and the Kaplan-
Meier estimator. The R package ROCR was used for the creation
of Receiver Operating Curve (ROC) plots and analysis of
accuracy, specificity, sensitivity and area under the curve.
Results
Demographics of patient population
Inclusion criteria were entry on the spleen registry, an available
blood sample for a full blood count including blood film, and IgM
memory B cells. Two groups of patients were analyses in this
study. The first group of patients (n=45) were incident cases that
were enrolled during their hospital admission or during immediate
follow-up and followed prospectively by the registry after
splenectomy. These cases were all related to trauma and had
routine hematological measures including blood film assessing for
the presence of Howell Jolly Bodies from the time of admission.
The second group consisted of 209 patients enrolled in the VSR at
any time after splenectomy and were used in the cross-sectional
analysis. Some demographics of this population are shown in
Table 1A. This population was similar to the registry populations
Table 1. Demographics of spleen registry populations.
A. Spleen registry population studied for IgM memory B cells
Number Male (%) Malignancy (%) Deaths (%) Age at registration (IQR)
,1 mth post-
operation (%)
Trauma 96(45.9) 61(64) 0 4(4.1) 45.3(31.7–57.3) 33(46)
Haematological 40(19.1) 14(35) 10(25) 3(7.5) 51.6(42.1–63.1) 2 (5)
Surgical 41(19.6) 19(46.3) 16(39) 2(4.8) 67.9(57.5–75.5) 12(29)
Other 8(3.8) 2(25) 0 0 54.3(37.8–70.7) 2(25)
Hyposplenic 5(2.4) 2(40) 0 0 46.5(42.7–68.0) NA
Embolization 19(9.1) 16(84.2) 0 4(21) 35.7(22.1–48.0) 17(89)
Total 209 114(54.5) 26(12) 13(6) 50.8(36.2–63.7) 66(32)
B. Spleen registry population not available for IgM memory B cells
Trauma 154(40.3) 108(70.1) 0 16(10.4) 43.5(27.5–54.4) 71(46)
Haematological 116(30.4) 50(43.1) 30(25.9) 7(6.0) 50.6(36.7–61.2) 23 (20)
Surgical 61(16.0) 33(54.1) 33(54.1) 6(9.8) 46.7(52.6–73.3) 26(43)
Other 34(8.9) 15(44.1) 3(8.8) 0 48.2(36.6–58.2) 8(24)
Hyposplenic 7(1.8) 2(28.6) 0 0 38.9(16.1–52.9) NA
Embolization 10(2.6) 5(50%) 0 4(40) 28.1(23.4–40.1) 7(70)
Total 382 213(56) 36(17) 33(9) 47.7(33.5–65.1) 135(35.3)
NS NS NS NS NS
Demographics of the patients with available blood test for IgM memory B cells (A) and those without an available result (B). The gender distribution (male), frequency of
malignancy and death, and frequency of early registration (,1month post operation) were compared by Chi squared test. The age at registration was compared by
Wilcoxon test and is shown as median and interquartile range (IQR). NS=not significant, NA=not applicable.
doi:10.1371/journal.pone.0023164.t001
IgM Memory B Cells after Splenectomy
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23164IgM Memory B Cells after Splenectomy
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23164that were untested for B cell subsets as shown in Table 1B. The
two populations were comparable in age, sex and indication for
splenectomy. Within both groups, as expected, males were more
common in the trauma group, older age more common where
splenectomy was incidental to an associated surgical procedur-
e,and malignancy was most frequent in surgical and hematological
groups.
Comparison of assays for IgM memory B cells
Initial assays for IgM memory B-cells was performed using a 3
colour flow cytometric analysis as shown in figure 1. The marker
CD19 was used to identify B cells and CD27 to identify the
memory cell subset. IgM memory B cells were identified as cells
expressing IgM, CD27, and CD19 within the lymphocyte
population identified by forward and side scatter characteristics.
The second assay method used for measurement of IgM memory
B cells used 5 colour analysis including CD45 to more accurately
exclude any residual RBCs from the analysis (Figure 1B).
Comparison between the 3 colour assay and the 5 colour total
white cell assays are shown in figure 2 where a sample set were
analyzed by both assays. Reference ranges for the different control
groups were comparable and there was good correlation between
samples tested on both assays.
Changes in IgM memory B cell numbers after
splenectomy
A normal laboratory control population (n=15) was compared
to patients from the spleen registry (n=209) using the 3 colour
assay. Splenectomy was found to be associated with a decreased
proportion of both the total memory cell population and the IgM
Figure 2. Comparison of 3 colour and 5 colour assays. Distribution of normal laboratory controls used for 3 colour (n=15) and 5 colour assays
(n=20) is shown. These 2 control populations were composed of different sets of laboratory controls recruited at different times. Left column
indicates the correlations between results for a cohort of patients assayed as fresh samples by both 3 colour and 5 colour assays. The right column
represents replicates in each assay with 3 colour assay shown in black and the 5 colour assay in red. Correlation was determined by Pearson product
moment correlation for 3 colour (black) and 5 colour (red) analyses. Box-plot show the median as the horizontal line in the middle of the box, 25% as
the lower end of the box 75% as the upper end and whiskers show the range.
doi:10.1371/journal.pone.0023164.g002
Figure 3. Distribution of B cell subsets in normal and hyposplenia individuals by indication for splenectomy. Subjects were classified
by indication for splenectomy and compared to normal laboratory controls (n=15). Normal=normal controls, Trauma=splenectomy related to
trauma, Haem=haematological disease, Surg=splenectomy incidental to abdominal surgery, Embol=splenic embolization. Box-plots show the
median as the horizontal line in the middle of the box, 25% as the lower end of the box 75% as the upper end and whiskers show the range.
Bonferroni corrected p values determined by Wilcoxon non-parametric statistic * ,0.05, ** ,0.001, *** ,0.0001 for comparisons to normal controls.
doi:10.1371/journal.pone.0023164.g003
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We then analyzed patients from the spleen registry according to
the underlying disease leading to splenectomy (Figure 3) to
determine if there was any effect of the underlying pathological
process on the distribution of B cells subsets after splenectomy. A
significant reduction in all memory B cell subsets was found for
splenectomized patients compared to the normal reference
population (p,0.01 for memory B cells/lymphocyte, p,0.001
for IgM memory B cells/lymphocytes, p,0.00001 for IgM
memory B cells/B cells). There was no effect of underlying
pathology on the proportion of total B cells, memory B cells or
IgM memory B cells. Patients with a history of splenic artery
embolization for traumatic spleen injury did not differ significantly
from normal controls in the proportions of the B cell sub-
populations (uncorrected p values=0.5 for B cells, 0.1 for memory
B cells, 0.07 for IgM memory B cells, and 0.15 for IgM memory B
cells/B cells).
Kinetics of splenectomy related change in B cells and
hematological parameters
To further determine if the differences between patients
following splenectomy or splenic artery embolization was due to
difference in the time at which the sample was collected relative to
the time of splenectomy or embolization, we next examined the
kinetics of changes in memory B cells after splenectomy using a
cross-sectional analysis of the splenectomy population. We used
the first sample from any patient with repeat assays (n=12).
We assumed that the underlying indication for the splenectomy
had no effect on the decay of IgM memory B cells and
demonstrated an apparent exponential decline in IgM memory
B cells within the first 100–150 days but stable levels beyond this
time (Figure 4). The selected trauma group showed the same
pattern of decrease shown in the total splenectomy population
(corrected p values=0.008, 0.0128, 0.008 for the 100–1000,
1000–10000 and .10000 days post splenectomy).
We next examined changes in lymphocyte and platelet numbers
over time in a subset of patients followed from the time of
splenectomy (Figure 5A,B). There was an increase in platelets and
lymphocytes with a peak in platelets at 20 days and lymphocytes at
approximately 50 days. We then examined the kinetics of
appearance of HJB on blood film. The appearance was rapid
with 50% of subjects having HJB present by 25 days (Figure 5C).
We then analysed the changes in IgM memory B cells in this group
of subjects (figure 5D). The pattern of loss in this population was
similar to that found in the cross-sectional analysis of the larger
population. In the patients with measurement of IgM memory B
cells at 2 time points the decline was similar to those with single
measurement.
Figure 4. Kinetics of changes in B cell subsets after splenectomy. The time in days post-splenectomy for registry patients was determined
from date of splenectomy to date of sample collection and plotted against proportion of lymphocytes represented by B cell numbers (i), memory B
cells (ii), and IgM memory B cells (iii) and IgM memory B cells as proportion of total B cells (iv). Data covering periods 1–10 days, 10–100 days, 100–
1000 days, 10000–100001 days and .10000 days were pooled for analysis. Only the analysis at the first assessment for each patient is shown and
repeat measures shown in red were excluded from statistical analysis. Box-plot show the median as the horizontal line in the middle of the box, 25%
as the lower end of the box 75% as the upper end and whiskers show the range. Outliers are omitted from the box-plots. The grey box-plot
represents the normal reference range for the assay. Bonferroni corrected p values determined by Wilcoxon non-parametric statistic * ,0.05,
** ,0.001, *** ,0.0001 for comparisons to normal controls.
doi:10.1371/journal.pone.0023164.g004
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To establish the reference range and to determine the predictive
value of IgM memory B cell measurement, we examined a
population of normal blood donors using 5 colour flow cytometry.
The reference population (n=105) was normal blood bank
donors. Blood from the normal donors was processed on the day
of venepuncture and the different B cell populations identified by
flow cytometry. To determine the performance of the IgM
memory B cell assays as markers of splenectomy a comparison
population of patients (n=24) more than 2 years after splenectomy
was used (Figure 6). Using the optimal cut-off for IgM memory B
cells as a proportion of total B cells of 4.53, we found a true
positive rate of 95% and false positive rate of 20%. Other
parameters including total memory B cells, and switched memory
B cells had lower AUC and were less predictive value for splenic
loss.
Age related changes in B cells in normal donor
populations
Since there was a trend to increased levels of IgM memory B
cells in our laboratory control populations compared to the blood
bank donor population we sought to analyze the donors by age
and gender. We compared these populations and showed no
significant decrease in IgM memory B cells by age in the healthy
blood donor population but a decrease in B cells and memory B
cells with age in the splenectomy population (Table 2). There was
no effect of gender. We further analyzed the contribution of age at
splenectomy and time of follow-up to determine if there was
evidence of a difference in IgM memory cells persistence where
splenectomy was performed at an early age. A significant negative
correlation was found with age at splenectomy and B and memory
B cells but not in the proportion of IgM memory B cells (figure S2).
No correlation was found for changes in memory B cells or B cells
by time of follow-up.
Clinical associations with changes in IgM memory B cell
numbers
We looked for association between memory B cell numbers and
infectious complications of splenectomy using a patient survey. Of
registry patients with available IgM memory B cell determination,
152 responded to a survey of infection risk in the preceding 12
months (response rate of 73%, table S1). Patients with IgM
memory B cells above the cut-off were more likely close to the time
of splenectomy and less likely to have detectable HJB but these
differences where not significant when the analysis was restricted
to those where IgM memory B cells were measured more than 200
days after splenectomy. No association of low IgM memory B cells
with infection, antibiotic use or hospitalization with infection was
found. No registered patients experienced OPSI during the study.
The registry population in the survey had high levels of
compliance with annual influenza vaccination (71%), and
prophylactic or emergency supply of antibiotics (63%).
Discussion
In this study we examined the changes in B cell subpopulations
in a cohort of patients enrolled in a spleen registry. The main
finding in these populations was a significant decrease in total
CD27+ memory B cells and in the IgM+IgD+CD27+IgM
memory B cells compared to normal controls. There was no
association between the number in the B cell subsets and the
underlying indication for splenectomy; trauma, haematological
disease, incidental surgical procedure or other medical disease.
The decline in IgM memory B cells after splenectomy was slower
than for changes in blood film parameters and reached a stable
nadir within 6 months after splenectomy. In contrast, appearance
of other markers for splenic dysfunction was more rapid with
median time to appearance of HJB at 25 days, a peak in
thrombocytosis at 20 days and a peak in post-splenectomy
lymphocytosis at 50 days. These findings suggested that the half-
life of IgM memory B cells in blood may be longer than for
changes in other indicators of splenic RBC clearance. Further it
suggests that measurement of IgM memory cells is not a good
indicator of the presence of splenic tissue until 6 months after
splenectomy.
This is the largest study of memory B cell subsets in
splenectomized patients with varying indications for splenectomy.
A number of smaller studies have examined IgM memory B cells
in splenectomized subjects [13,17,35]. Initial work that examined
the relationship between IgM memory B cell numbers and
splenectomy suggested that there was complete loss of IgM
memory B cells but the sample size was small (n=11) [13] and
included subjects late after splenectomy(0.5–9 years). Another
study showed that B cell populations in the blood of asplenic
children (n=10) was reduced but not absent [14]. In a comparison
of memory B cells, IgM memory B cells and antibody responses to
vaccination it was found that there was no difference in antibody
responses between controls and those with splenectomy for
spherocytosis [17] but decreased IgM responses and reduced
IgM memory B cells in those with splenectomy for Idiopathic
Thrombocytopenic Purpura (ITP). This difference may be due to
the differences in timing of splenectomy in these populations or to
persistence of some alternative reservoir of IgM memory B cells
after splenectomy at an early age.
Changes in IgM memory B cells with age have been reported
[17], with one study reporting dramatic decline in memory B cells
with advancing age [36]. In normals we found no significant
relationship between age and total B cells, memory B cells, and
IgM memory B cells. After splenectomy we found age related
decrease in B cells and memory B cells but no significant
correlation with IgM memory B cells as proportion of memory B
cells suggesting that splenectomy related changes affect B cell
homeostasis beyond IgM memory cells alone. Although there are
early changes of lymphocytosis and thrombocytosis associated with
splenectomy we found a delayed decline in IgM memory B cells
with a long period with stable low levels after an initial apparently
Figure 5. Kinetics of change in haematological parameters and IgM memory B cells after splenectomy. Incident cases of splenectomy
(n=51) were examined for changes in haematological parameters on sequential blood films and automated lymphocyte and platelet counts. A]
Changes in platelet count post splenectomy. The data points and the geometric mean and 95% confidence intervals for repeat measure ANOVA for
observations divided into deciles by time are shown on a log time scale. B] Changes in lymphocyte numbers post splenectomy. Similar analysis as
shown in A. C] Kaplan Meier plot of rate of appearance of asplenic changes including HJB on blood film. The analysis was performed on a subset of
patients (n=45) with absence of HJB on the first analysis. The 95% confidence intervals for the function are shown by grey dashed lines. Median time
to appearance of HJB was 25 days. D] Changes in IgM memory B cells as proportion of B cells with time. Relationship between IgM memory B cells
and time post splenectomy was determined in the subset shown in C with available IgM assay (n=42). Single values are plotted as a dot-plot and
sequential data (n=12) are shown as line plot overlay. A linear regression and 95% confidence interval (grey) is fitted for the single data point and the
sequential samples (open box). The grey histogram indicates the range for the normal controls.
doi:10.1371/journal.pone.0023164.g005
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clearance from the blood after their splenic source of origin is
removed and that there are alternative sources of the IgM memory
B cells accounting for low but persistent numbers. Previous
research in man has shown a faster turnover of CD27+ memory
compared to naı ¨ve B cells [37] but this study did not divide the
CD27+ memory B cells populations by IgD or IgM expression to
identify IgM memory cells and switched memory B cells and was
not performed in asplenic subjects [37]. The IgM memory cell
population may include distinct sub-populations with different
rates of turnover. B cell receptor sequencing data indicates a
proportion of the IgM expressing memory B cells may derive from
the germinal center reaction [38,39]. Murine marginal zone IgM+
memory cells have a slow turnover and are restricted to the spleen
[32] however one recent study has addressed the question of loss of
IgM memory B cells after splenectomy in patients with ITP and
shown a more rapid loss of IgM memory B cells than switched
memory B cells [18]. Our cross-sectional data on kinetics of loss
does agree with these authors’ findings of decline of IgM memory
B cells within 8 months of splenectomy to a stable level up to more
than 2 years [18]. This persistent reduced but stable level after the
initial decline is consistent with a pool of IgM memory cells with
long half life or more likely with IgM memory B cell populations
derived from germinal centre reactions outside the spleen. Both
possibilities would reduce the value of IgM memory B cell assays as
biomarkers of functional splenic tissue.
Age related changes may be important in the interpretation of
the reference populations. An increase in memory cells with age
has been reported with approximately 30% memory B cells in
young subjects rising to 45% in elderly [37]. Sources of IgM
memory B cells other than from the spleen [38] may also affect the
rate of decay in IgM memory B cells after splenectomy at a young
age is suggested by the observations of persistence of IgM memory
B cells after splenectomy for spherocytosis compared to ITP [17].
We were unable to differentiate between different sources of IgM
memory B cells but have demonstrated that in the early post
operative period both memory B cells and IgM memory B cells are
normal.
The clinical significance of loss of IgM memory B cells in
humans has only been established indirectly through the
association of low IgM memory cells with complications of
asplenia. The risk of OPSI has been attributed to both reduced
clearance of bacteria as evident by presence of abnormal red cells
indicated by presence of HJB and the loss of IgM memory B cells
which provide innate immune responses [13]. The assumption
that only marginal zone IgM memory B cells serve an innate
defence role however has been questioned [40]. Recent work has
suggested that the CD27+ B cells which will include the IgM
memory cell population may be divided by CD43 expression into
a B1 cell population that is responsible for production of natural
antibody and IgM production [41], functions attributed to IgM
memory B cells [13]. In mouse CD5+ B1 cells (B1a) although not
exclusively localized to the spleen do depend on the spleen for
production and maintenance [42]. There is a need for further
study to directly determine the relationship between vaccine
responses to polysaccharide vaccines according to the levels of IgM
memory B cells including both germinal centre derived IgM
memory B cells and B1 cells in both asplenic and normal
individuals.
Our data indicating high false negative rate suggests that
conventional measurement of IgM memory B cells alone may not
be useful in identifying asplenia or in identification of subjects at
risk for OPSI. It may however supplement the detection of HJB in
the identification of patients at risk for hyposplenism for further
assessment of splenic function by other methods [43].
This study has some limitations: i] we did not assess for function
of the populations of IgM memory B cells. Currently it is
considered that circulating IgM memory B cells in addition to
representing a) circulating splenic marginal zone B cells may
include b) germinal center B cells from various sites that have not
been subject to class switch [39] and may be functionally similar to
switched memory B cells, and c) B1 cells [41]. Cells with the
phenotype of IgM memory B cells may have splenic origins by a
distinct pathway that is critical for early response to T cell
independent polysaccharide antigens [44–46]. This is supported
by recent B cell receptor sequencing data [38,39] and by murine
Figure 6. Reference ranges for B cell subsets in normal donors and asplenic patients. A] Five colour flow cytometry was used to measure
the number of CD19+ B cells, CD27+ memory B cells, IgM memory B cells and CD27+IgM2 switched B cells. Normal laboratory donors (lab donors
n=20), Red Cross Blood Transfusion Service donors (RCBTS, n=105) and samples from patients at least 12 months after splenectomy (splenectomy,
n=36) were tested and results expressed as proportion of lymphocytes or of B cells. box-plots show the median as the horizontal line in the middle
of the box, 25% as the lower end of the box 75% as the upper end and whiskers show the range. B] Receiver operator curves were used to analyse
each of the 4 parameters including CD19+CD27+ memory B cells, IgM memory B cells, CD27+IgM2IgD2 switched memory B cells, and IgM memory
B cells as proportion of B cells as discriminators between normal and asplenic individuals. Area under the curve for each plot is shown in B. The
relationship of accuracy against cut-off is plotted in A with the box-plots.
doi:10.1371/journal.pone.0023164.g006
Table 2. Effects of age and gender on B cell subsets after splenectomy in mixed model analysis.
Age Male gender
logEst logStderr logPvalue logEst logStderr logPvalue
% B cells 20.006 0.002 0.001 20.129 0.11 0.24
% mB cells 20.010 0.002 ,0.001 20.059 0.13 0.65
% IgM mB cells 20.011 0.002 ,0.001 20.017 0.139 0.902
% IgM mB/B cells 20.005 0.002 0.014 0.121 0.126 0.339
% IgM mB/mB 0.0 0.001 0.714 0.074 0.065 0.259
Data was log transformed to normalize the distribution and the effects of age and gender on B cell subpopulations were determined. Populations included B cell (% B
cells), memory B cells (% mB cells) and IgM memory B cells (IgM mB cells) as a proportion of lymphocytes, IgM memory B cells as a proportion of B lymphocytes( %I g M
mB/B cells) and IgM memory B cells as a proportion of memory B cells (% IgM mB/mB).
doi:10.1371/journal.pone.0023164.t002
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changes in IgM memory B cells after splenectomy will be critical in
determining the contribution of T cell independent IgM memory
B cell subpopulations to protection from OPSI. ii] Clinical events
are uncommon in the spleen registry population as we have
recently reported [47] and correlation between numbers within
subpopulations of IgM memory B cells and clinical events will
require large prospective studies on such populations. iii] In this
study we had limited longitudinal data as IgM memory B cells
were usually assayed on only one occasion around the time of
enrollment in the registry. The analysis of kinetic of IgM memory
cell loss that we performed may have been confounded by a
survival bias. iv] Two different assays were used in the study.
Initially we used a simple 3 colour cytometric assay using CD19,
CD27 and IgM that was later replaced by a 5 colour assay
including CD45 and IgD that has been adopted by the clinical
laboratory. The reference ranges for these assays were similar and
the samples that were assayed by both methods were found to
correlate. We have also compared our reference ranges to other
published studies of IgM memory B cells in different diseases using
different methods [13,17,19,25,48–52] and found a comparable
range for the controls [figure S3].
In summary we showed in a large spleen registry population
that there was a significant decrease in IgM memory B cells in
splenectomized subjects and that this was not related to the
indication for splenectomy. Our data suggest that measurement of
IgM memory B cells may be insensitive in the identification of
patient with functional splenic tissue and will have a limited role in
stratification of risk of OPSI or identifying risk of less severe
infections in splenectomized populations.
Supporting Information
Figure S1 Patient samples used in the study. IgM
memory B cell assays were performed at the time of entry for
209 of the the registry patients (n=591). This populations was
used to determine relationship between cause for splenectomy and
IgM memory B cells and in the analysis of changes in IgM
memory B cells with time following splenectomy. A subset of
‘‘incident’’ patients was used to determine haematological changes
in comparison to IgM memory B cells changes. 51 patients had
haematological data from the time of splenectomy of which 45 had
an initial blood film that did not show HJB and follow-up blood
films. Of these 42 had measurement of IgM memory B cells
including 12 with sequential measures. Two assays for IgM
memory B cells were used in this study; an initial 3 colour analysis
that was compared to a normal control population (n=15) and
later a 5 colour assay that was compared to a normal control
population (n=20). These 2 assays were directly compared for 48
samples including some non-registry patient samples and registry
patients. The reference values for this assay were established using
a normal blood bank donor population that was selected to cover
the adult age range and equally represent male and females. This
was compared by ROC analysis against a splenectomy population
that was more than 1 year post-splenectomy (n=24). Data was
obtained from patient survey of compliance with spleen registry
recommendations. The subset of patients tested for IgM memory
B cells (n=152) was then used to determine relationship between
the parameter ‘‘IgM memory B cells/B cells’’ and measures of
compliance and indicators of infection.
(TIF)
Figure S2 Correlation of changes in B cell subsets with
age at splenectomy and time post splenectomy. Patients
after splenectomy were analyzed for changes in proportion of B
cells, memory B cells, IgM memory B cells with age (left column).
The variable of changes in B cell with age was resolved into
comparisons of changes in B cells with time since splenectomy
(middle column) and changes with age at the time of splenectomy
(right column). The Pearson correlation and p values for the
correlations are shown above each plot.
(TIF)
Figure S3 Comparison of reference range from the
current study with other studies of IgM memory B cells
and B cell subsets. The summary data for healthy control
populations were taken from published studies and plotted as
mean and SD, median and IQR (blue) or median and range (red).
The size of the mean/median symbol is proportional to the log of
the number of subjects in the reference population. Each cell type
is shown as proportion of B cells (B) or of total lymphocytes (L).
(TIF)
Table S1 IgM memory B cells as a predictor of
infectious complications after splenectomy. Patients were
divided into 2 groups based on IgM memory B cell levels above
(.cutoff) or below (,cutoff) the cutoff determined by the ROC
analsysis shown in fig. 6. The 2 groups where then compared for
parameters determined from the patient survey. The initial
analysis (upper panel) found significant association with absent
HJB and had a nuber of patients at an early time post
splenectomy. The analysis was repeated after exclusion of subjects
where the IgM memory B cells had been determine less than 200
days after splenectomy.
(DOC)
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